Synthesis and anti-inflammatory activity of celecoxib like compounds

References

• Amir M, Kumar H, Khan SA. Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents. Bioorg Med Chem Lett 2008;18:918–922.
   PubMed Web of Science ®Google Scholar
• Rathish IG, Javed K, Ahmad S, Bano S, Alam MS, Pillai KK et al. Synthesis and antiinflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide. Bioorg Med Chem Lett 2009;19:255–258.
   PubMed Web of Science ®Google Scholar
• Gürsoy A, Demirayak S, Capan G, Erol K, Vural K. Synthesis and preliminary evaluation of new 5-pyrazolinone derivatives as analgesic agents. Eur J Med Chem 2000;35:359–364.
   PubMed Web of Science ®Google Scholar
• Bashir R, Ovais S, Yaseen S, Hamid H, Alam MS, Samim M et al. Synthesis of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide as anticancer and anti-inflammatory agents. Bioorg Med Chem Lett 2011;21:4301–4305.
   PubMed Web of Science ®Google Scholar
• Johnson M, Younglove B, Lee L, LeBlanc R, Holt H Jr, Hills P et al. Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. Bioorg Med Chem Lett 2007;17:5897–5901.
   PubMed Web of Science ®Google Scholar
• Rostom SA. Synthesis and in vitro antitumor evaluation of some indeno[1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. Bioorg Med Chem 2006;14:6475–6485.
   PubMed Web of Science ®Google Scholar
• Sahu SK, Banerjee M, Samantray A, Behera A, Azam MA. Synthesis, analgesic, anti-inflammatory and antimicrobial activities of some novel pyrazoline derivatives. Tropical journal of pharmaceutical research, 2008;7;961–968.
   Web of Science ®Google Scholar
• Chandra T, Garg N, Lata S, Saxena KK, Kumar A. Synthesis of substituted acridinyl pyrazoline derivatives and their evaluation for anti-inflammatory activity. Eur J Med Chem 2010;45:1772–1776.
   PubMed Web of Science ®Google Scholar
• Ahn JH, Kim HM, Jung SH, Kang SK, Kim KR, Rhee SD et al. Synthesis and DP-IV inhibition of cyano-pyrazoline derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett 2004;14:4461–4465.
   PubMed Web of Science ®Google Scholar
• Rojas J, Domínguez JN, Charris JE, Lobo G, Payá M, Ferrándiz ML. Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase. Eur J Med Chem 2002;37:699–705.
   PubMed Web of Science ®Google Scholar
• Bano S, Javed K, Ahmad S, Rathish IG, Singh S, Alam MS. Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents. Eur J Med Chem 2011;46:5763–5768.
   PubMed Web of Science ®Google Scholar
• Drew J. Drug discovery: a historical perspective. Science, 2000;287:1960–1964.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp Opin Ther Patents 2000;10:575–600.
   Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors. Curr Med Chem Immunol Endoc Metab Agents 2001;1:61–97.
   Google Scholar
• Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004;47:550–557.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Boyd AE 3rd. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes 1988;37:847–850.
   PubMed Web of Science ®Google Scholar
• Thornber CW. Isosterism and molecular modification in drug design. Chem Soc Rev 1979;8:563–580.
   Web of Science ®Google Scholar
• Ogden RC, Flexner CW. (2001). Protease Inhibitors in AIDS Therapy. New York, Basel: Marcel Dekker.
   Google Scholar
• Supuran C, Scozzafava A, Mastrolorenzo A. Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. Expert Opin Ther Patents 2001;11:221–259.
   Web of Science ®Google Scholar
• Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000;43:3677–3687.
   PubMed Web of Science ®Google Scholar
• Casini A, Scozzafava A, Mastrolorenzo A, Supuran LT. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets 2002;2:55–75.
   PubMed Web of Science ®Google Scholar
• Amgad G, Habeeb PN, Parveen R, Edward EK. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere. J Med Chem 2001;44:3039–3042.
   PubMed Web of Science ®Google Scholar
• Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 1962;111:544–547.
   PubMed Web of Science ®Google Scholar
• Daidone G, Maggio B, Raffa D. Synthesis and pharmacological study of ethyl 1-methyl-5-[2-substituted-4-oxo-3(4H)-quinazolinyl]-1H-pyrazole-4-acetates. Eur J Med Chem 1994;29:707–711.
   Google Scholar
• di Stasi LC, Costa M, Mendaçolli SL, Kirizawa M, Gomes C, Trolin G. Screening in mice of some medicinal plants used for analgesic purposes in the state of São Paulo. J Ethnopharmacol 1988;24:205–211.
   PubMed Web of Science ®Google Scholar
• Boyd MR. Am Assoc Cancer Res. 1989;30:652–663.
   Google Scholar
• Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757–766.
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Myers TG, O’Connor PM, Friend SH, Fornace AJ Jr, Kohn KW et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343–349.
   PubMed Web of Science ®Google Scholar
• Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci 1995;57:131–141.
   PubMed Web of Science ®Google Scholar
• Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992;19:622–638.
   PubMed Web of Science ®Google Scholar
• Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91–109.
   Web of Science ®Google Scholar
• Boyd MR. Status of the NCI preclinical antitumor drug discovery screen. Princ Pract Oncol 1989;3:1–12.
   Google Scholar